RecruitingPhase 2Drug trialEvaluating Genomic Testing in Human Cancer & Outcomes of Targeted TherapiesThis is a substudy (Part 2) of a larger two-part clinical trial including both observational and therapeutic (interventional) cohorts to assess the progression free survival ratio of patients treated with a targeted therapy based on genomic analysis results and recommendation by the Markey Cancer Center Molecular Tumor Board (MCC MTB).